Comparison of a standard BCG dose (81 MG) versus a three-fold reduced dose (27 MG) in high risk superficial bladder cancer (TIG3, TIS), A cueto prospective randomised study #95012

Martinez-Piñeiro, J.A.; Martinez-Piñeiro, L.; Solsona, E.; Rodríguez, Rafael Hernández; Gomez, Johnson; Martin, M. González; Molina, Jesús Rodríguez; Gimeno, A.; Flores, Nicolás; Isorna, Santiago; Pertusa, C; Rabadán, M; Astobieta, Ander; Camacho, Jancarlos

doi:10.1016/s1569-9056(03)80754-6

European Urology Supplements

2003

DOI: 10.1016/s1569-9056(03)80754-6

|View full text |Cite

Comparison of a standard BCG dose (81 MG) versus a three-fold reduced dose (27 MG) in high risk superficial bladder cancer (TIG3, TIS), A cueto prospective randomised study #95012

J.A. Martinez-Piñeiro¹,

L. Martinez-Piñeiro²,

E. Solsona³

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2004

2010

Publication Types

Select...

Article3

Relationship

Self Cite0

Independent3

Authors

Journals

Cited by 3 publications

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Comparison of a standard BCG dose (81 MG) versus a three-fold reduced dose (27 MG) in high risk superficial bladder cancer (TIG3, TIS), A cueto prospective randomised study #95012

Cited by 3 publications

References 0 publications

Intravesical therapy for superficial bladder cancer: A systematic review of randomised trials and meta-analyses

Intravesical therapy for superficial bladder cancer: A systematic review of randomised trials and meta-analyses

Bladder Carcinoma in Situ in 2003: State of the Art

Bladder Cancer—Resection/Ablation

Contact Info

Product

Resources

About